Cellectis (XPAR:ALCLS) Total Stockholders Equity : €83.32 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Cellectis Total Stockholders Equity?

Cellectis's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €83.32 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Cellectis's Book Value per Share for the quarter that ended in Mar. 2024 was €1.16. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Cellectis's Debt-to-Equity for the quarter that ended in Mar. 2024 was 1.04.

Cellectis Total Stockholders Equity Historical Data

The historical data trend for Cellectis's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Total Stockholders Equity Chart

Cellectis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

283.61

233.28

195.84

111.36

77.67

Cellectis Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															106.23	89.12	71.33	77.67	83.32

Cellectis (XPAR:ALCLS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Cellectis's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(83.321	-	0)	/	71.9555
	=	1.16

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Cellectis's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(12.373	+	74.303)	/	83.321
	=	1.04

Cellectis Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Cellectis's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis (XPAR:ALCLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (XPAR:ALCLS) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

CMVLF:USA CLLS:USA 0WA2:UK ZVAA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (XPAR:ALCLS) Headlines

No Headlines